This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	SMAD family member 4 (DPC4)	<p>Postmortem tissue studies of pancreatic cancer patients suggest that <i>DPC4</i> gene status at initial diagnosis could help guide selection of treatment regimens. Immunolabeling the pancreatic cancer tissue samples showed that 22% of locally advanced and 78% of metastatic cancers had a loss in <i>DPC4</i>. Next steps could include determining whether <i>DPC4</i> status is correlated with treatment outcome.</p> <p>SciBX 2(12); doi:10.1038/scibx.2009.488 Published online March 26, 2009</p>	Patent and licensing status unavailable	<p>Iacobuzio-Donahue, C. <i>et al.</i> <i>J. Clin. Oncol.</i>; published online March 9, 2009; doi:10.1200/JCO.2008.17.7188</p> <p>Contact: Christine A. Iacobuzio-Donahue, Johns Hopkins Medical Institutions, Baltimore, Md. e-mail: ciacobu@jhmi.edu</p>